Medullary thyroid carcinoma identified within the first year of life in children with hereditary multiple endocrine neoplasia type 2A (codon 634) and 2B.

CONTEXT Early prophylactic thyroidectomy in patients with multiple endocrine neoplasia (MEN) type 2 offers the best chance for a normal life expectancy. OBJECTIVE To analyze the results of thyroidectomy performed during the first year of life in six patients with MEN 2A (codon 634) or MEN 2B (codon 918) syndrome. DESIGN AND SETTING A university hospital-based prospective study from 2001 to 2008. SUBJECTS AND METHODS Six family members affected either by MEN 2A (n=3) or MEN 2B (n=3) syndrome were identified through neonatal genetic screening. RESULTS Total thyroidectomy was performed at a median age of 0.8 year in the six patients, with central lymph node dissection in five. Bilateral millimetric medullary thyroid carcinoma (MTC) was found in all patients, with a unilateral lymph node micrometastasis in two of the three MEN 2B patients. Before thyroidectomy, MEN 2B patients had much higher basal serum calcitonin levels than those with MEN 2A and controls. After thyroidectomy, with a median follow-up of 3.3 years, the six patients had no evidence of persistent MTC. CONCLUSION Bilateral millimetric MTC may be present during the first year of life in these patients, with lymph node metastases also occurring in MEN 2B patients. These results support a total thyroidectomy at the age of about one year in MEN 2A (codon 634) children with an abnormal serum calcitonin level, and a total thyroidectomy with central neck dissection within the first weeks of life in MEN 2B patients.

[1]  S. Hauptmann,et al.  Medullary thyroid cancer responsiveness to pentagastrin stimulation: an early surrogate parameter of tumor dissemination? , 2008, The Journal of clinical endocrinology and metabolism.

[2]  W. Bremner,et al.  Advances in male contraception. , 2008, Endocrine reviews.

[3]  C. Bieglmayer,et al.  Medullary thyroid microcarcinoma recommendations for treatment - a single-center experience. , 2007, Surgery.

[4]  S. Bielack,et al.  Medullary thyroid carcinoma in a 2-month-old male with multiple endocrine neoplasia 2B and symptoms of pseudo-Hirschsprung disease: a case report. , 2007, Journal of pediatric surgery.

[5]  S. Hauptmann,et al.  Increased Risk of Lymph Node Metastasis in Multifocal Hereditary and Sporadic Medullary Thyroid Cancer , 2007, World Journal of Surgery.

[6]  S. Hauptmann,et al.  Locoregional recurrence and death from medullary thyroid carcinoma in a contemporaneous series: 5-year results. , 2007, European journal of endocrinology.

[7]  H. Buhr,et al.  Long-term outcome in 46 gene carriers of hereditary medullary thyroid carcinoma after prophylactic thyroidectomy: impact of individual RET genotype. , 2006, European journal of endocrinology.

[8]  P. Jouk,et al.  Very early prophylactic thyroid surgery for infants with a mutation of the RET proto‐oncogene at codon 634: evaluation of the implementation of international guidelines for MEN type 2 in a single centre , 2006, Clinical endocrinology.

[9]  P. Beck‐Peccoz,et al.  Normal Range of Calcitonin in Children Measured by a Chemiluminescent Two-Site Immunometric Assay , 2006, Hormone Research in Paediatrics.

[10]  R. Hofstra,et al.  RET as a diagnostic and therapeutic target in sporadic and hereditary endocrine tumors. , 2006, Endocrine reviews.

[11]  E. Baudin,et al.  How effective is prophylactic thyroidectomy in asymptomatic multiple endocrine neoplasia type 2A? , 2006, Nature Clinical Practice Endocrinology &Metabolism.

[12]  K. Owzar,et al.  Prophylactic thyroidectomy in multiple endocrine neoplasia type 2A. , 2005, The New England journal of medicine.

[13]  Malaka B. Jackson,et al.  Multiple Endocrine Neoplasia Type 2A in a Kindred With C634Y Mutation , 2005, Pediatrics.

[14]  P. Tsao,et al.  Excess Soluble fms-Like Tyrosine Kinase 1 and Low Platelet Counts in Premature Neonates of Preeclamptic Mothers , 2005, Pediatrics.

[15]  H. Holzhausen,et al.  Prospects of remission in medullary thyroid carcinoma according to basal calcitonin level. , 2005, The Journal of clinical endocrinology and metabolism.

[16]  H. Dralle,et al.  Advances in the management of hereditary medullary thyroid cancer , 2005, Journal of internal medicine.

[17]  C. Sekulla,et al.  Multiple Endocrine Neoplasia 2B Syndrome due to Codon 918 Mutation: Clinical Manifestation and Course in Early and Late Onset Disease , 2004, World Journal of Surgery.

[18]  D. Jaeck,et al.  When should thyroidectomy be performed in familial medullary thyroid carcinoma gene carriers with non-cysteine RET mutations? , 2003, Surgery.

[19]  H. Dralle,et al.  Early malignant progression of hereditary medullary thyroid cancer. , 2003, The New England journal of medicine.

[20]  A. Maia,et al.  RET codon 634 mutations in multiple endocrine neoplasia type 2: variable clinical features and clinical outcome. , 2003, The Journal of clinical endocrinology and metabolism.

[21]  E. Baudin,et al.  Rationale for central and bilateral lymph node dissection in sporadic and hereditary medullary thyroid cancer. , 2003, The Journal of clinical endocrinology and metabolism.

[22]  R. Hofstra,et al.  Acceptable age for prophylactic surgery in children with multiple endocrine neoplasia type 2a. , 2003, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[23]  P. Komminoth,et al.  Review of multiple endocrine neoplasia type 2A in children: therapeutic results of early thyroidectomy and prognostic value of codon analysis. , 2003, Pediatrics.

[24]  H. Domené,et al.  Very early detection of RET proto‐oncogene mutation is crucial for preventive thyroidectomy in multiple endocrine neoplasia type 2 children , 2002, Cancer.

[25]  J. Bilezikian,et al.  Guidelines for diagnosis and therapy of MEN type 1 and type 2. , 2001, The Journal of clinical endocrinology and metabolism.

[26]  John P. Bilezikian,et al.  CONSENSUS: Guidelines for Diagnosis and Therapy of MEN Type 1 and Type 2 , 2001 .

[27]  V. Rohmer,et al.  Familial medullary thyroid carcinoma with noncysteine ret mutations: phenotype-genotype relationship in a large series of patients. , 2001, The Journal of clinical endocrinology and metabolism.

[28]  M. Schlumberger,et al.  Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma: results in 899 patients , 1998 .

[29]  P. Caron,et al.  Interest of routine measurement of serum calcitonin: study in a large series of thyroidectomized patients. The French Medullary Study Group. , 1997, The Journal of clinical endocrinology and metabolism.

[30]  C Eng,et al.  The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis. , 1996, JAMA.

[31]  al. et,et al.  Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B , 1995, Science.

[32]  R. Hofstra,et al.  A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma , 1994, Nature.

[33]  B. Ponder,et al.  Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A , 1993, Nature.

[34]  S. Baylin,et al.  Familial medullary thyroid carcinoma without associated endocrinopathies: A distinct clinical entity , 1986, The British journal of surgery.

[35]  A. Tashjian,et al.  C-cell hyperplasia preceding medullary thyroid carcinoma. , 1973, The New England journal of medicine.

[36]  J. Doppman,et al.  Sipple's syndrome: medullary thyroid carcinoma, pheochromocytoma, and parathyroid disease. Studies in a large family. NIH conference. , 1973, Annals of internal medicine.

[37]  E. Baudin,et al.  Medullary thyroid carcinoma as part of a multiple endocrine neoplasia type 2B syndrome , 2002, Cancer.

[38]  W. Cunliffe,et al.  A calcitonin-secreting medullary thyroid carcinoma associated with mucosal neuromas, marfanoid features, myopathy and pigmentation. , 1970, The American journal of medicine.